<DOC>
	<DOCNO>NCT00657449</DOCNO>
	<brief_summary>The study compare valdecoxib 40 mg daily vs. rofecoxib 50 mg one daily treat sign symptom acute first- second-degree ankle sprain . The study also evaluate disability status , tolerability safety treatment .</brief_summary>
	<brief_title>A Double-Blind , Double-Dummy , Multicenter , Randomized Study Efficacy Tolerability Valdecoxib 40 mg Versus Rofecoxib 50 mg Treating Symptoms Ankle Sprain</brief_title>
	<detailed_description>This study terminate early 30 September 2004 due safety concern around continued usage rofecoxib follow withdrawal rofecoxib worldwide market Merck &amp; Co Inc .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Ankle Injuries</mesh_term>
	<mesh_term>Sprains Strains</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Valdecoxib</mesh_term>
	<criteria>Patients sustain , 48 hour prior first dose study medication , first seconddegree ankle sprain lateral ligament , specifically : anterior talofibular ligament and/or posterior talofibular ligament and/or calcaneofibular ligament At presentation , patient Patient 's Assessment Ankle Pain Visual Analog Scale ( VAS ) ( 0100mm ) â‰¥45 mm orthostatic position full weight bearing ( ie , moderate severe pain ) , minimum rating 2 Patient 's Global Assessment Ankle Injury Patient 's Assessment Normal Function/Activity Tthe investigator opinion patient require , eligible , therapy antiinflammatory agent and/or analgesic control symptoms None report</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>sprain strain</keyword>
</DOC>